IART
Integra LifeSciences Holdings Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
16.91
▲ 0.32 (1.93%)
MARKET · —
Price
Open
16.83
Prev close
16.59
Day high
16.94
Day low
16.44
Volume
524.41K
Market cap
$1.30B
P/E (TTM)
—
52W range
8.70 – 20.49
Trailing performance
Returnvs SPY
1W
-8.72%
-7.4%
1M
-9.81%
-13.5%
3M
+10.71%
+7.6%
6M
+37.10%
+26.0%
YTD
+34.78%
+22.5%
1Y
+17.39%
-2.6%
3Y
-61.19%
-135.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.30B
Enterprise value$3.08B
Revenue (TTM)$1.65B
Gross profit$937.07M
EBITDA$316.92M
Net income$-7.24M
EPS (TTM)$-0.09
Free cash flow$94.40M
Total cash$274.08M
Total debt$2.05B
Book value / share$13.42
Shares outstanding77.77M
Float58.68M
Short % of float11.48%
Dividend yield—
Beta (5Y)1.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E6.43
PEG ratio0.67
Price / sales—
Price / book1.25
EV / revenue1.87
EV / EBITDA9.71
Gross margin56.87%
Operating margin9.62%
Profit margin-0.44%
Return on equity-0.70%
Return on assets2.83%
Debt / equity196.49
Current ratio3.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.64B | $1.61B | $1.54B | $1.56B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.48 | 0.56 | +16.5% |
| Mar 2026 | 0.40 | 0.54 | +33.4% |
| Dec 2025 | 0.80 | 0.83 | +3.7% |
| Sep 2025 | 0.43 | 0.54 | +24.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.56 | 11 | $416.30M | +3.5% |
| Next quarter | 0.80 | 11 | $447.37M | +2.9% |
| Current year | 2.46 | 12 | $1.67B | +2.4% |
| Next year | 2.61 | 12 | $1.73B | +3.2% |
Analyst targets & ownership
Mean target$19.56
High target$27.00
Low target$14.00
Implied upside15.64%
Analyst count9
ConsensusNONE
Strong buy / Buy1 / 2
Hold7
Sell / Strong sell0 / 2
Held by insiders14.30%
Held by institutions98.23%
Institutions holding298
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
11.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 7, 26 | HILL BARBARA BENTON Director |
STOCK | 24.34K | $0 | Direct |
| Mar 11, 26 | SINGH HARVINDER Officer |
— | 20.14K | — | Direct |
| Jan 6, 26 | POUL MOJDEH Chief Executive Officer |
— | 1.39K | — | Direct |
| Nov 5, 25 | GRAVES JEFFREY A. Director |
BUY | 9.00K | $102.15K | Direct |
| Oct 10, 25 | SINGH HARVINDER Officer |
— | 11.96K | — | Direct |
| May 9, 25 | BRADLEY KEITH Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | ESSIG STUART PH.D. Officer and Director |
STOCK | 31.84K | $0 | Direct |
| May 9, 25 | HILL BARBARA BENTON Director |
STOCK | 26.53K | $0 | Direct |
| May 9, 25 | SCHADE CHRISTIAN S Director |
STOCK | 26.53K | $0 | Direct |
| May 9, 25 | GRAVES JEFFREY A. Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | CLAY SHAUNDRA Director |
STOCK | 19.59K | $0 | Direct |
| May 9, 25 | LO RENEE WONLAI Director |
STOCK | 19.59K | $0 | Direct |
| Mar 11, 25 | DAVIS ROBERT T JR Officer |
STOCK | 12.43K | $0 | Direct |
| Mar 11, 25 | MOSEBROOK JEFFREY Officer |
STOCK | 5.51K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRADLEY KEITH |
Director | 89.14K | Stock Award(Grant) |
CLAY SHAUNDRA |
Director | 41.52K | Stock Award(Grant) |
DAVIS ROBERT T JR |
Officer | 75.56K | Stock Award(Grant) |
ESSIG STUART PH.D. |
Officer and Director | 1.79M | Stock Award(Grant) |
GRAVES JEFFREY A. |
Director | 41.09K | Purchase |
HILL BARBARA BENTON |
Director | 187.54K | Stock Award(Grant) |
KNIGHT LEA DANIELS |
Chief Financial Officer | 61.14K | Stock Award(Grant) |
MCBREEN MICHAEL J |
Officer | 70.34K | Stock Award(Grant) |
SCHADE CHRISTIAN S |
Director | 90.03K | Stock Award(Grant) |
SCHWARTZ ERIC IAN |
Officer | 59.51K | Sale |
Moving averages & technicals
SMA 10
17.42
-2.92% from price
SMA 20
17.58
-4.76% from price
SMA 50
17.99
-6.94% from price
SMA 100
15.44
+9.52% from price
SMA 200
13.54
+23.67% from price
EMA 12
17.38
-2.70% from price
EMA 26
17.62
-4.05% from price
EMA 50
17.30
-2.26% from price
RSI (14)
42.3
Neutral
MACD (12,26,9)
-0.25
Hist -0.11
ATR (14)
0.70
4.19% of price
Realised vol 30D
69.1%
Annualised
Bollinger upper
19.28
20, 2σ
Bollinger lower
15.87
20, 2σ
50 / 200 cross
Golden
17.99 vs 13.54
Trend bias
Above 200
+23.67%
Risk profile
Beta vs SPY
2.06
More volatile than market
Correlation to SPY
0.43
Loosely linked
Realised vol 30D
69.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-44.8%
Peak to trough
Max drawdown 5Y
-88.3%
Peak to trough
ATR 14
0.70
4.19% of price
Beta (reported)
1.21
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.17
Put-heavy session
Put / call open interest
0.57
Positioning, not flow
Max pain
12.50
-25.3% from spot
ATM implied vol
52.1%
Nearest strike to spot
Skew (10% OTM)
+9.7%
Puts bid over calls
Call volume
35
Contracts, this expiry
Put volume
41
Contracts, this expiry
Heaviest call OI
20.00
75 contracts
Heaviest put OI
7.50
90 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Zacks · 2d ago
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Zacks · 3d ago
3 Stocks Under $50 with Questionable Fundamentals
StockStory · 4d ago
3 Value Stocks We Steer Clear Of
StockStory · 5d ago
2 Russell 2000 Stocks with Solid Fundamentals and 1 We Find Risky
StockStory · 8d ago
Integra (IART) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
5 Must-Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call
StockStory · 15d ago
Integra LifeSciences Holdings (IART) Returns To Profit As Fair Value Debate Stays In Focus
Simply Wall St. · 20d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.